Jill L Wright

US Patent:

20090142806, Jun 4, 2009

Filed:

Aug 21, 2008

Appl. No.:

12/196117

Inventors:

BEATRIZ M. CARRENO - CLAYTON MO, US
MARY COLLINS - NATICK MA, US
JILL F. WRIGHT - ASHLAND MA, US
NEIL M. WOLFMAN - DOVER MA, US
MAYA ARAI - BROOKLINE MA, US
KENNETH JACOBS - NEWTON MA, US
ZHIJIAN LU - BEDFORD MA, US
YONGJING GUO - CHESTNUT HILL MA, US
YONGCHANG QIU - ACTON MA, US

Assignee:

WYETH - MADISON NJ

International Classification:

C12P 21/04
C07K 14/54

US Classification:

435 6952, 530351

Abstract:

The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

US Patent:

20110033451, Feb 10, 2011

Filed:

Jun 30, 2010

Appl. No.:

12/827199

Inventors:

Beatriz M. Carreno - Clayton MO, US
Mary Collins - Natick MA, US
Jill F. Wright - Ashland MA, US
Neil M. Wolfman - Dover MA, US
Maya Arai - Brookline MA, US
Kenneth Jacobs - Newton MA, US
Zhijian Lu - Bedford MA, US
Yongjing Guo - Chestnut Hill MA, US
Yongchang Qiu - Acton MA, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

A61K 39/395
A61K 33/24
A61K 38/02
A61K 31/7088
A61P 11/06
A61P 29/00
A61P 19/02
A61P 17/06

US Classification:

4241331, 4241301, 424649, 514 11, 514 44 A

Abstract:

The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.